How Mdoloris Can Measure Pain Through Artificial Intelligence

[ad_1]

Already present in 66 countries, the northern start-up is housed within the Eurasanté incubator.

The company, which has 38 employees, was founded by Fabien Pagniez, holder of a master's degree in health engineering and a graduate of HEC. It is based on research on heart rate variability initiated in 1987 by Professor Régis Logier.

"Mdoloris comes from an academic research program led by Inserm and the University Hospital of Lille who turned 23. They have developed a patented technology capable of monitoring the pain felt by a patient conscious or not and this is where the company was born in June 2010 ", explained to TICsanté Fabien Pagniez.

Specifically, to effectively measure patient pain, Mdoloris has developed continuous, non-invasive medical monitoring devices for hospital practitioners.

"The company's business is to develop, manufacture and market medical devices, and we have entered the healthcare market for hospitals and clinics since it was there that doctors were looking for a reliable technology to measure the pain of patients, especially when they are not communicating and they can not indicate their level of pain: anesthetized, in intensive care, infants, autistic, end of life … ", has it -he adds.

In these situations, "the medical profession is in a cloud of uncertainty concerning the good match between the pain-killing drugs to be administered to a patient and his real needs".

Devices adapted to the age and type of patients

Mdoloris technology is based on obtaining a comfort index, scientifically evaluated on a numerical value between 0 and 100.

A high index reflects optimal comfort as in periods of developmental care, while a low index reveals discomfort that may be caused by the realization of care, postoperative pain or adverse environment.

This index is calculated from an electrocardiogram (ECG) multiparametric monitoring provided to monitoring pain in a comfort zone between 60 and 70 and allow the practitioner to properly calibrate the dose of analgesics.

"Overdose of opioids causes nausea and vomiting upon waking, prolongs waking time and failure of the immune system, and in 40% of cases, overdose causes hypersensitivity to postoperative pain, hyperalgesia, which can last up to three years after the surgical operation, "explained Fabien Pagniez.

"In the context of an underdose, the body will respond to the pain by setting alarm and increasing the heart rate, blood pressure etc. and the patient is no longer stable on the operating table and this causes an inflammatory response of the body, "he added.

Through biosensors, here electrodes, and AI algorithms, the technology can analyze the ECG and identify the pain. For this, Mdoloris has declined its technology into three medical devices.

• For patients older than "two years"

Technology analgesia nociception index (ANI), which assesses the level of comfort or pain of patients over two years hospitalized has been marketed by Mdoloris since 2016. The young push claims nearly 1,000 copies sold and 150,000 patients monitored.

"Exposure to stress during the first 1,000 days of the newborn can increase the risk of developing long-term cardiovascular and metabolic pathologies and can lead to depressive, addictive or inappropriate responses to pain. or stress, "said the start-up.

Through monitoring heart rate variability and interpretation of the index newborn infant parasympathetic evaluation (Nipe) developed by Mdoloris, the medical teams can optimize the comfort of the big premature baby to the 2 years old child.

Until then, the assessment of well-being was based on the observation of its general behavior (cries, crying, facial and body movements …) This index aims to provide a scientific understanding of the pain felt by the newborn. The tool, non-invasive, is able to evaluate in real time and in a continuous way the well-being of the hospitalized children.

Finally, a last module is for animals.

A business model based on a "package"

Mdoloris, whose products are "entirely made in Lille", was able to count quite early in its history on a first fundraising to get started. In 2010, the start-up, which then only a few months, rounded a series of round of table A of 1.4 million euros.

All of its devices have won their CE marking since its creation. In 2013, to accelerate production, Mdoloris raised 2.5 million euros.

Winner of several regional and national innovation competitions, the company carried out two other fundraisings in 2016 (5 million euros) and 2019 (9 million euros).

In 2019, the start-up also signed a global partnership with the US leader in monitoring devices, Masimo, listed on Nasdaq, for international distribution.

"In general, the monitoring for adults costs the end customer 10.000 euros, the one for neonatology costs 15 000. The sensors, they cost 3,000 to 4,000 euros per monitoring and per year," explained Fabien Pagniez.

"These are devices that have proven their utility in the operating room and in intensive care," he said. "There is no need to equip the entire hospital."

In addition, Mdoloris is also working on an R & D project to develop "a solution that can be used at health home, with a textile technology such as a t-shirt smart health connected with sensors and smart health connected to a cloud secure where the data will be transmitted, "said the leader of the Lille start-up.

In parallel, several clinical studies have been conducted for 23 years and "167 studies are in progress in the 66 countries" where the company is present, he concluded.

[ad_2]